MA62175B1 - Promédicament de dérivés de pyrrolidone en tant qu'activateur de glucokinase - Google Patents
Promédicament de dérivés de pyrrolidone en tant qu'activateur de glucokinaseInfo
- Publication number
- MA62175B1 MA62175B1 MA62175A MA62175A MA62175B1 MA 62175 B1 MA62175 B1 MA 62175B1 MA 62175 A MA62175 A MA 62175A MA 62175 A MA62175 A MA 62175A MA 62175 B1 MA62175 B1 MA 62175B1
- Authority
- MA
- Morocco
- Prior art keywords
- promedication
- glucokinase activator
- pyrrolidone derivatives
- compound
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
La présente invention concerne un composé de formule (I), ou un produit à marquage isotopique, un énantiomère, un diastéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci ; une composition pharmaceutique comprenant un composé de formule (I) ; et l'utilisation d'un composé de formule (I) ou d'une composition pharmaceutique de celui-ci dans le traitement du diabète sucré et de symptômes apparentés.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111079620 | 2021-09-15 | ||
| CN202211093895 | 2022-09-08 | ||
| EP22782445.5A EP4244221B1 (fr) | 2021-09-15 | 2022-09-15 | Promédicament de dérivés de pyrrolidone en tant qu'activateur de glucokinase |
| PCT/CN2022/118947 WO2023040937A1 (fr) | 2021-09-15 | 2022-09-15 | Promédicament de dérivés de pyrrolidone en tant qu'activateur de glucokinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA62175B1 true MA62175B1 (fr) | 2026-02-27 |
Family
ID=83505858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA62175A MA62175B1 (fr) | 2021-09-15 | 2022-09-15 | Promédicament de dérivés de pyrrolidone en tant qu'activateur de glucokinase |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US12054477B2 (fr) |
| EP (2) | EP4244221B1 (fr) |
| JP (1) | JP7751731B2 (fr) |
| KR (1) | KR20240044465A (fr) |
| CN (1) | CN117940419A (fr) |
| AR (1) | AR127064A1 (fr) |
| AU (1) | AU2022346020A1 (fr) |
| CA (1) | CA3231566A1 (fr) |
| CL (1) | CL2024000738A1 (fr) |
| CO (1) | CO2024002748A2 (fr) |
| DK (1) | DK4244221T3 (fr) |
| EC (1) | ECSP24020925A (fr) |
| ES (1) | ES3063045T3 (fr) |
| FI (1) | FI4244221T3 (fr) |
| GE (1) | GEP20267848B (fr) |
| HR (1) | HRP20260241T1 (fr) |
| IL (1) | IL311237A (fr) |
| JO (1) | JOP20240055A1 (fr) |
| LT (1) | LT4244221T (fr) |
| MA (1) | MA62175B1 (fr) |
| MD (1) | MD4244221T2 (fr) |
| MX (1) | MX2024003068A (fr) |
| PE (1) | PE20240933A1 (fr) |
| PL (1) | PL4244221T3 (fr) |
| PT (1) | PT4244221T (fr) |
| RS (1) | RS67759B1 (fr) |
| SI (1) | SI4244221T1 (fr) |
| SM (1) | SMT202600065T1 (fr) |
| TW (1) | TW202328107A (fr) |
| WO (1) | WO2023040937A1 (fr) |
| ZA (1) | ZA202402086B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021243646A1 (fr) * | 2020-06-04 | 2021-12-09 | Hua Medicine (Shanghai) Ltd. | Activateur de glucokinase pour le traitement du diabète à insuffisance hépatique |
| AR132113A1 (es) * | 2023-03-13 | 2025-05-28 | Hua Medicine Shanghai Ltd | Forma sólida de derivados de pirrolidona como activador de glucoquinasa |
| IL325046A (en) | 2023-06-06 | 2026-02-01 | Hua Medicine Shanghai Ltd | Activates glucokinase for cognitive disorders and neurodegenerative diseases |
| AU2024400384A1 (en) | 2023-12-14 | 2026-07-09 | Hua Medicine USA Inc. | Pharmaceutical formulation comprising glucokinase activator and use thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710205B2 (en) | 2000-02-22 | 2004-03-23 | Ono Pharmaceutical Co., Ltd. | Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| EP1939181A1 (fr) | 2006-12-27 | 2008-07-02 | sanofi-aventis | Carboxamides hétérocycliques et leur utilisation pour la stimulation de l'expression de la NO synthase |
| WO2009126782A1 (fr) | 2008-04-11 | 2009-10-15 | High Point Pharmaceuticals, Llc | Ligands du récepteur h<sb>3</sb> de l'histamine |
| US20120058937A9 (en) * | 2008-04-15 | 2012-03-08 | Tsrl, Inc. | Prodrugs of Neuraminidase Inhibitors |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| US8258134B2 (en) * | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
| WO2010048149A2 (fr) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie |
| CN102264737A (zh) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | 抗病毒化合物 |
| WO2012129562A2 (fr) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Composés et procédés pour l'induction de la chondrogenèse |
| US8772541B2 (en) | 2011-12-15 | 2014-07-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases |
| US9388168B2 (en) * | 2012-12-25 | 2016-07-12 | Hua Medicine | Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1H-pyrazol-3-ylamine |
| HK1252693A1 (zh) | 2015-06-30 | 2019-05-31 | Dana Farber Cancer Institute, Inc. | Egfr抑制剂及其使用方法 |
| WO2017066705A1 (fr) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Composés, compositions et méthodes d'utilisation contre des granules de stress |
| DK3556354T3 (da) | 2016-12-15 | 2025-08-04 | Hua Medicine Shanghai Ltd | Oral fremstilling af en glucokinaseaktivator og fremgangsmåde til fremstilling deraf |
| US11358940B2 (en) | 2017-04-20 | 2022-06-14 | The Regents Of The University Of California | K-Ras modulators |
| BR112020024269A2 (pt) * | 2018-05-31 | 2021-02-23 | Hua Medicine (Shanghai) Ltd. | combinação farmacêutica, composição e formulação de combinação contendo ativador de glucoquinase e ativador de receptor ppar e métodos de preparação e usos dos mesmos |
| TW202043198A (zh) | 2019-01-17 | 2020-12-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關之病況的化合物及組合物 |
| US10689360B1 (en) | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
| US11008303B2 (en) | 2019-01-30 | 2021-05-18 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| WO2022040604A1 (fr) | 2020-08-21 | 2022-02-24 | BioAge Labs, Inc. | Utilisation d'antagonistes du récepteur dp1 pour le traitement d'infections virales des voies respiratoires et de la réponse immunitaire dérégulée chez des patients âgés et vieillissants |
-
2022
- 2022-09-14 AR ARP220102495A patent/AR127064A1/es unknown
- 2022-09-15 MA MA62175A patent/MA62175B1/fr unknown
- 2022-09-15 MX MX2024003068A patent/MX2024003068A/es unknown
- 2022-09-15 FI FIEP22782445.5T patent/FI4244221T3/fi active
- 2022-09-15 SI SI202230245T patent/SI4244221T1/sl unknown
- 2022-09-15 MD MDE20230915T patent/MD4244221T2/ro unknown
- 2022-09-15 CA CA3231566A patent/CA3231566A1/fr active Pending
- 2022-09-15 IL IL311237A patent/IL311237A/en unknown
- 2022-09-15 GE GEAP202416483A patent/GEP20267848B/en unknown
- 2022-09-15 KR KR1020247007444A patent/KR20240044465A/ko active Pending
- 2022-09-15 PE PE2024000460A patent/PE20240933A1/es unknown
- 2022-09-15 PT PT227824455T patent/PT4244221T/pt unknown
- 2022-09-15 DK DK22782445.5T patent/DK4244221T3/da active
- 2022-09-15 CN CN202280061260.2A patent/CN117940419A/zh active Pending
- 2022-09-15 PL PL22782445.5T patent/PL4244221T3/pl unknown
- 2022-09-15 HR HRP20260241TT patent/HRP20260241T1/hr unknown
- 2022-09-15 ES ES22782445T patent/ES3063045T3/es active Active
- 2022-09-15 LT LTEPPCT/CN2022/118947T patent/LT4244221T/lt unknown
- 2022-09-15 JP JP2024516664A patent/JP7751731B2/ja active Active
- 2022-09-15 SM SM20260065T patent/SMT202600065T1/it unknown
- 2022-09-15 RS RS20260203A patent/RS67759B1/sr unknown
- 2022-09-15 TW TW111134935A patent/TW202328107A/zh unknown
- 2022-09-15 AU AU2022346020A patent/AU2022346020A1/en active Pending
- 2022-09-15 WO PCT/CN2022/118947 patent/WO2023040937A1/fr not_active Ceased
- 2022-09-15 EP EP22782445.5A patent/EP4244221B1/fr active Active
- 2022-09-15 EP EP25220029.0A patent/EP4714442A3/fr active Pending
-
2023
- 2023-06-12 US US18/333,459 patent/US12054477B2/en active Active
-
2024
- 2024-03-05 CO CONC2024/0002748A patent/CO2024002748A2/es unknown
- 2024-03-13 ZA ZA2024/02086A patent/ZA202402086B/en unknown
- 2024-03-13 CL CL2024000738A patent/CL2024000738A1/es unknown
- 2024-03-14 JO JOJO/P/2024/0055A patent/JOP20240055A1/ar unknown
- 2024-03-15 EC ECSENADI202420925A patent/ECSP24020925A/es unknown
- 2024-06-18 US US18/746,554 patent/US20240336597A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA58181B1 (fr) | Composés tricycliques substitués | |
| MA29564B1 (fr) | Formulation de 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile | |
| MA65131B1 (fr) | Utilisation d'un inhibiteur d'ezh2 dans la préparation d'un médicament pour le traitement d'un lymphome à cellules t | |
| MA58004B1 (fr) | Dérivés de pyrazolyle utiles en tant qu'agents anticancéreux | |
| MA46101B1 (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA30890B1 (fr) | Compose indole | |
| MA47368B1 (fr) | N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga | |
| MA30999B1 (fr) | Composés. | |
| MA47469B1 (fr) | Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer | |
| MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
| MA45020B1 (fr) | Dérivés sulfonamides aromatiques | |
| MA31894B1 (fr) | Composes organiques | |
| MA27774A1 (fr) | Inhibiteurs de phosphatidylinositol 3-kinase | |
| TNSN99053A1 (fr) | Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant | |
| CA2656716C (fr) | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique | |
| MA29377B1 (fr) | Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif | |
| MA26696A1 (fr) | Derives de tetrahydrobenzazepine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA29411B1 (fr) | 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa | |
| MA29543B1 (fr) | Procedes pour traiter un cancer pharmacoresistant | |
| MA32283B1 (fr) | Composes cycliques condenses et utilisation de ceux-ci | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| EP4162937A4 (fr) | Composition pharmaceutique pour la prévention ou le traitement de la maladie de parkinson, comprenant un composé du type 2-(4-(1-hydroxypropane-2-yl)phényl)isoindolin-1-one | |
| JOP20210329A1 (ar) | مركبات بيرازول مزدوجة الاستبدال كمثبطات كيتو هيكسو كيناز | |
| MA29969B1 (fr) | Formulations de quinolinones | |
| MA31388B1 (fr) | Utilisation d'un composé i pour prévenir ou traiter une formation de biofilm |